Jeffrey J. Kimbell & Associates, INC.
lobbying firm
Jeffrey J. Kimbell & Associates, INC.'s federal footprint as a lobbying firm — reported lobbying it billed or handled on behalf of the clients it represents (this is the firm's reported revenue for that work, not its own spending). Figures are as reported to the U.S. Senate (LDA).
Reported country: 🇺🇸 United States
Lobbying over time
| FY | Lobbying billed / handled (as firm) |
|---|---|
| 2022 | $4,461,000 |
| 2023 | $4,345,250 |
| 2024 | $6,572,250 |
| 2025 | $4,525,000 |
Reported lobbying revenue for the clients Jeffrey J. Kimbell & Associates, INC. represents — not the firm's own spending.
Clients represented
- Gilead Sciences, INC. $1,350,000 · 18 filings
- Biogen INC. $1,020,000 · 20 filings
- U.S. Renal Care $900,000 · 18 filings
- Boehringer Ingelheim Pharmaceuticals, INC. $760,000 · 19 filings
- Astellas Pharma Us $760,000 · 19 filings
- Accuray Incorporated $760,000 · 19 filings
- Brookdale Senior Living INC. $720,000 · 18 filings
- Ardelyx, INC. $680,000 · 18 filings
- Livanova USA INC $600,000 · 20 filings
- Nevro Corporation $560,000 · 14 filings
Clients Jeffrey J. Kimbell & Associates, INC. filed lobbying for, by reported amount billed/handled.
Issues
| Issue area | Worked |
|---|---|
| Health Issues | 659 |
| Medicare/Medicaid | 391 |
| Trade (domestic/foreign) | 35 |
| Defense | 28 |
| Housing | 18 |
| Manufacturing | 12 |
| Tariff (miscellaneous tariff bills) | 10 |
| Agriculture | 9 |
| Veterans | 9 |
| Environment/Superfund | 7 |
| Financial Institutions/Investments/Securities | 6 |
| Budget/Appropriations | 4 |
| Insurance | 2 |
| Medical/Disease Research/Clinical Labs | 2 |
| Pharmacy | 2 |
| Copyright/Patent/Trademark | 1 |
| Science/Technology | 1 |
Issue areas across Jeffrey J. Kimbell & Associates, INC.'s filings, by activity count. Linked areas open the CivicGate issue page.
What they lobbied on
Reported activity from Senate LDA
-
FY2025 Health Issues
Issues related to behavioral healthcare companies
-
FY2025 Medicare/Medicaid
Issues related to Medicare Part B and Part D
-
FY2025 Health Issues
Issues related to the pharmaceutical industry
-
FY2025 Health Issues
issues related to the PACE program
-
FY2025 Medicare/Medicaid
issues relevant to the PACE program
-
FY2025 Health Issues
Issues related to behavioral healthcare companies and substance use services
-
FY2025 Medicare/Medicaid
Issues related to apheresis access and reimbursement
-
FY2025 Trade (domestic/foreign)
Issues related to supply chain constraints
Show 52 more activities
-
FY2025 Medicare/Medicaid
issues related to allergy & asthma reimbursement
-
FY2025 Medicare/Medicaid
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
-
FY2025 Health Issues
Issues related to the regulation of gene therapies; newborn screening; FDA appropriations
-
FY2025 Medicare/Medicaid
allergy & asthma issues
-
FY2025 Health Issues
Issues related to coverage of medical devices
-
FY2025 Medicare/Medicaid
Issues related to coverage of medical devices
-
FY2025 Health Issues
Issues related to drug approval
-
FY2025 Health Issues
Issues related to medical devices
-
FY2025 Medicare/Medicaid
Issues related to Medicare rebates
-
FY2025 Health Issues
Issues related to the regulation of pharmaceuticals
-
FY2025 Health Issues
Issues related to the Federal Employees Compensation Act (FECA)
-
FY2025 Financial Institutions/Investments/Securities
issues related to financial regulations and private equity
-
FY2025 Health Issues
Issues related to medical products
-
FY2025 Trade (domestic/foreign)
Issues related to trade
-
FY2025 Medicare/Medicaid
Issues related to Medicare payment for/access to radiation therapy services
-
FY2025 Trade (domestic/foreign)
issues related to tariffs and trade
-
FY2025 Medicare/Medicaid
Issues related to Medicare rebates
-
FY2025 Health Issues
Issues related to the regulation of pharmaceuticals
-
FY2025 Medicare/Medicaid
Issues related to reimbursement for gene therapies. H.R. 7389, MVP Act of 2022
-
FY2025 Health Issues
Issues related to the regulation of gene therapies; newborn screening; FDA appropriations
-
FY2025 Health Issues
Issues related to hepatitis C and prescription drugs
-
FY2025 Health Issues
issues related to the medical device industry and incentivizing new technology
-
FY2025 Medicare/Medicaid
issues related to reimbursement for implantable medical devices
-
FY2025 Health Issues
Issues related to the development and approval of therapies for rare diseases
-
FY2025 Health Issues
issues related to senior health care
-
FY2025 Housing
issues related to senior housing
-
FY2025 Health Issues
Issues related to the pharmaceutical industry and Medicare drug reimbursement
-
FY2025 Medicare/Medicaid
Issues related to the pharmaceutical industry and Medicare drug reimbursement
-
FY2025 Health Issues
Issues related to the development and approval of therapies for rare diseases
-
FY2025 Medicare/Medicaid
Medicare reimbursement of pharmaceuticals
-
FY2025 Health Issues
general issues of interest to pharmaceutical companies
-
FY2025 Health Issues
Issues related to coverage of medical devices
-
FY2025 Medicare/Medicaid
Issues related to coverage of medical devices
-
FY2025 Health Issues
Issues related to Hepatitis C and prescription drugs
-
FY2025 Health Issues
issues related to the practice of allergy treatment
-
FY2025 Medicare/Medicaid
coverage of allergy treatment
-
FY2025 Health Issues
Issues related to behavioral healthcare companies and substance use services
-
FY2025 Medicare/Medicaid
Issues related to Medicare rebates
-
FY2025 Health Issues
Issues related to the regulation of pharmaceuticals
-
FY2025 Health Issues
Issues related to FDA regulation of rare disease therapies
-
FY2025 Medicare/Medicaid
Issues related to Medicare Part B and Part D
-
FY2025 Health Issues
Issues related to the pharmaceutical industry
-
FY2025 Health Issues
Issues related to pharmaceutical drugs
-
FY2025 Health Issues
issues related to pharmaceutical drugs
-
FY2025 Health Issues
Issues related to combination product development
-
FY2025 Health Issues
issues related to the pharmaceutical industry
-
FY2025 Medicare/Medicaid
issues related to Medicare drug reimbursement
-
FY2025 Health Issues
issues related to medical device regulation
-
FY2025 Health Issues
issues related to pharmaceutical drugs
-
FY2025 Defense
Issues Related to Defense and Human Performance
-
FY2025 Health Issues
Issues related to prescription drugs
-
FY2025 Health Issues
issues related to pharmaceutical drugs
The specific issues and bills Jeffrey J. Kimbell & Associates, INC. reported lobbying on, newest first. Bill references that CivicGate tracks link to the bill; others are shown as reported.